Comparison of Ondansetron and Palonosetron on Postoperative Nausea and Vomiting in Patients Undergoing Maxillofacial Surgery: A Prospective Randomized Double-Blind Clinical Trial

昂丹司琼与帕洛诺司琼对颌面外科手术患者术后恶心呕吐疗效的比较:一项前瞻性随机双盲临床试验

阅读:1

Abstract

PURPOSE: The aim of this study was to evaluate the effectiveness of intravenous ondansetron in comparison with palonosetron during the first 24 hours post-maxillofacial surgery. MATERIALS AND METHOD: A prospective, randomized, double-blind, clinical trial was carried out in 40 patients who underwent Maxillofacial surgery under general anesthesia. Patients were randomized to receive either ondansetron 4 mg (group A) or palonosetron 0.075 mg (group B), administered by intravenous injection 30 min prior to intubation. A coin-flipping randomization method was used. Nausea and vomiting incidence was assessed after every one hour for the first 6 hours and then from 6 to 24(th) hours postoperatively. RESULTS: The current study result shows that overall incidence of postoperative nausea and vomiting is 50% {nausea (n = 13) + vomiting (n = 7)} in both the groups after maxillofacial surgeries during 6(th) to 24(th) hours. However, the efficacy of ondansetron and palonosetron is equal in early hours with statistically not significant. Palonosetron is slightly more effective than ondansetron in late hours with statistically not significant. As per Apfel's scoring system, both groups have almost equal risk scores (group A, 1 = 3, 2 = 11, 3 = 6) and (group B, 1 = 4, 2 = 10, 3 = 6). CONCLUSION: Both ondansetron and palonosetron are equally effective for the early postoperative hours (first six hours); thereafter, palonosetron is slightly more effective than ondansetron in the late postoperative period (6(th) to 24th hours) for the prevention of PONV following Maxillofacial surgeries under general anesthesia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。